Introduction
Anemia affects more than 2 billion people globally — approximately 25% of the world’s population — making it the most common blood disorder and one of the most significant contributors to the global burden of disease (World Health Organization, 2025). Iron-deficiency anemia alone accounts for approximately 50% of all anemia cases and is the leading cause of years lived with disability among women of reproductive age. For patients with sickle cell disease (SCD), which affects over 100,000 individuals in the United States and millions worldwide, anemia severity is directly associated with complications including end-organ damage, stroke risk, and poor quality of life. Yet the gold standard for hemoglobin measurement — the complete blood count (CBC) requiring venipuncture — remains invasive, episodic, and costly. Medical wearables capable of non-invasive hemoglobin estimation are poised to transform hematology care by enabling frequent, painless monitoring that supports early detection of anemia, optimization of treatment, and improved quality of life for patients with chronic blood disorders. This B2B OEM guide examines the technology, clinical validation, and manufacturing considerations for wearable hematology devices.
The Technology: Non-Invasive Hemoglobin Estimation
Photoplethysmography-Based Methods
The most mature approach to non-invasive hemoglobin estimation leverages photoplethysmography (PPG) — the same optical technology used in pulse oximeters and smartwatches. Hemoglobin has characteristic light absorption spectra that vary with oxygen saturation and concentration. By measuring the absorption of light at multiple wavelengths through the vascular bed of the finger or wrist, algorithms can estimate hemoglobin concentration.
A 2025 study published in Computer Modeling in Engineering & Sciences demonstrated a novel adaptive lightweight convolutional neural network (HMALCNN) that estimated hemoglobin concentration from multi-wavelength PPG signals. The model, validated on two multi-regional datasets with different spectral configurations (dual- and four-wavelength PPG), achieved clinically acceptable accuracy with a root-mean-square error (RMSE) within the FDA’s acceptance criteria for non-invasive hemoglobin monitors (±1 g/dL). Importantly, Gradient-weighted Class Activation Mapping (Grad-CAM) analysis confirmed that the model attended to physiologically relevant PPG waveform features — including systolic peaks and dicrotic notches — rather than learning spurious correlations.
The WHO classification of anemia severity by hemoglobin level provides the clinical context for these measurements:
| Population | Mild Anemia | Moderate Anemia | Severe Anemia |
|
|
|
–|
|
| Men ≥15 years | 11–12.9 g/dL | 8–10.9 g/dL | <8 g/dL |
| Women ≥15 years | 11–11.9 g/dL | 8–10.9 g/dL | <8 g/dL |
| Pregnant women | 10–10.9 g/dL | 7.7–9.9 g/dL | <7 g/dL |
| Children 6–59 months | 10–10.9 g/dL | 7–9.9 g/dL | <7 g/dL |
A wearable achieving ±1 g/dL accuracy can reliably classify anemia severity across these categories, enabling population-level screening and individual-level monitoring.
Smartphone-Based Methods
An alternative approach, developed by Sanguina, Inc. and validated in clinical studies published in Nature Communications (2018) and PNAS (2025), uses smartphone camera images of the fingernail bed to estimate hemoglobin concentration. The app, which has been downloaded more than 250,000 times and used for over 1.6 million tests since its December 2021 launch, demonstrated a mean absolute error of ±0.57 g/dL (R = 0.96) in pediatric sickle cell disease patients — comparable to the accuracy of point-of-care hemoglobinometers used in clinical settings.
In a 2025 study presented at the American Society of Hematology (ASH) annual meeting, 30 pediatric SCD patients (ages 6 months to 17 years) used the app every other day for 12 weeks, achieving 85% compliance — higher than the adult study cohort and demonstrating the acceptability of non-invasive monitoring in pediatric populations. The ability to accurately measure hemoglobin in children as young as 6 months, without the anxiety and pain of venipuncture, represents a significant advance in pediatric hematology care.
Multi-Modal Approaches
The most promising direction for wearable hematology monitoring combines multiple sensor modalities. A 2026 comprehensive review published in EBioTrade examined non-invasive anemia detection systems using PPG, spectrophotometry, and optical coherence tomography (OCT) across different anatomical sites — conjunctiva, nail bed, palm, lip, and retina — and concluded that multi-modal fusion frameworks combining imaging data with clinical metadata achieved the highest accuracy. The review identified dataset bias, hardware variability, and the need for prospective clinical validation as the key barriers to clinical deployment.
Clinical Applications
Sickle Cell Disease Management
SCD is a paradigm case for wearable hematology monitoring. Patients experience both chronic anemia and acute complications — vaso-occlusive crises, acute chest syndrome, splenic sequestration — that are associated with rapid changes in hemoglobin concentration. The SCD-CARRE trial, a 12-month multi-site randomized controlled trial funded by the NIH, demonstrated that continuous wearable monitoring (using Garmin devices) was feasible in 85% of high-risk SCD patients, with mean wear time of 21.5 hours per day. While the trial focused on activity and heart rate monitoring, the addition of hemoglobin estimation capability would provide a more complete picture of disease status.
For patients on hydroxyurea — the most common disease-modifying therapy for SCD, taken by 14 of 30 participants in the Sanguina pediatric study — frequent hemoglobin monitoring supports dose optimization, as hydroxyurea’s myelosuppressive effect requires balancing anemia risk against the benefit of fetal hemoglobin induction.
Iron-Deficiency Anemia Screening
The WHO recommends universal anemia screening for pregnant women and children under 5 in high-prevalence settings. In low-resource environments where laboratory infrastructure is limited, wearable or smartphone-based hemoglobin estimation could enable population-level screening at a fraction of the cost of conventional methods. A 2025 WHO technical consultation on innovative anemia diagnostics identified non-invasive technologies as a priority for accelerating progress toward the global nutrition target of 50% reduction in anemia prevalence among women of reproductive age by 2030.
Chemotherapy-Induced Anemia Monitoring
Cancer patients receiving myelosuppressive chemotherapy experience predictable declines in hemoglobin that can be managed with erythropoiesis-stimulating agents (ESAs) or red blood cell transfusions. Continuous hemoglobin monitoring via a wearable device would enable more precise timing of interventions, potentially reducing unnecessary transfusions (which carry risks of alloimmunization, transfusion reactions, and volume overload) while ensuring that severely anemic patients receive timely treatment.
Perioperative Blood Management
The World Health Organization’s Patient Blood Management (PBM) framework emphasizes the importance of preoperative anemia detection and correction to reduce transfusion requirements and improve surgical outcomes. A wearable hemoglobin monitor worn during the weeks before elective surgery would enable detection and treatment of preoperative anemia — which affects 30–40% of surgical patients and is independently associated with increased morbidity and mortality.
OEM Manufacturing Considerations
Multi-Wavelength Optical Design
Accurate PPG-based hemoglobin estimation requires sensors operating at multiple wavelengths — typically including green (525 nm), red (660 nm), and infrared (940 nm) — to capture the differential absorption spectra of oxyhemoglobin and deoxyhemoglobin. Four-wavelength configurations add near-infrared (1300 nm) for improved tissue penetration and reduced melanin interference. The optical design must balance LED power consumption, photodetector sensitivity, and signal-to-noise ratio within the tight packaging constraints of a wearable device.
Skin Tone Independence
A persistent challenge in optical biosensing is the performance variation across skin tones. Melanin absorbs light in the visible spectrum, reducing the signal-to-noise ratio for PPG measurements in individuals with darker skin. The FDA’s 2025 draft guidance on pulse oximeter performance emphasizes the need for clinical validation in diverse populations, and the same principle applies to hemoglobin estimation. OEM designs should incorporate multi-wavelength compensation, adaptive LED intensity, and machine learning models trained on diverse datasets to minimize performance disparities.
Motion Artifact Rejection
PPG signals are highly susceptible to motion artifacts, which can introduce errors far exceeding the clinical accuracy requirement of ±1 g/dL. Advanced signal processing techniques — including adaptive filtering, wavelet denoising, and accelerometer-based motion compensation — are essential for reliable measurements during daily activities. The 2025 HMALCNN study demonstrated that attention-based deep learning models that focus on physiologically relevant waveform features are inherently more robust to motion artifacts than traditional signal processing approaches.
Regulatory Pathway
Non-invasive hemoglobin monitors are classified as Class II devices by the FDA (Product Code: DQC) and typically require 510(k) clearance. The FDA has cleared several non-invasive hemoglobin measurement devices, including Masimo’s SpHb (Rainbow SET platform) and Medtronic’s NIRS-based regional oximetry systems, providing established predicate devices for the 510(k) pathway. Key performance requirements include:
– Accuracy: Arms (accuracy root mean square) ≤ 1.5 g/dL compared to reference laboratory CO-oximetry
– Precision: Coefficient of variation ≤ 5% for repeated measurements
– Interference testing: Demonstration that common interferents (bilirubin, lipids, carboxyhemoglobin, methemoglobin) do not produce clinically significant errors
Conclusion
Non-invasive hemoglobin monitoring via medical wearables addresses one of the largest unmet needs in global health: the ability to detect and monitor anemia without needles, laboratories, or clinic visits. For the 2 billion people living with anemia, the 100,000 Americans with sickle cell disease, and the millions of surgical and oncology patients who would benefit from optimized blood management, wearable hematology devices offer a future of more frequent, less burdensome, and more personalized care. For B2B OEM buyers, the technology is maturing rapidly, the regulatory pathway is defined, and the market opportunity is measured in billions of lives.
Contact Geyan Technology Innovation to explore custom wearable development for non-invasive hematology monitoring. Our OEM/ODM services deliver multi-wavelength optical sensors, regulatory-grade algorithms, and clinically validated solutions for hemoglobin estimation and blood disorder management.
📧 jine@xdunmedical.com | 📞 +86-13544254314